ArticleClinical cancer research : an official journal of the American Association for Cancer Research2013
Harnessing immune responses in the tumor microenvironment: all signals needed.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 17 citations in OpenAlex.
- T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma.JCI insight · 2018Trial
- Clinical application and drug resistance mechanism of gemcitabine.Frontiers in cell and developmental biology · 2025Review
- Potential of mRNA vaccines to become versatile cancer vaccines.World journal of clinical oncology · 2022Review
- Cancer vaccine strategies: translation from mice to human clinical trials.Cancer immunology, immunotherapy : CII · 2018Review
- Transient and Local Expression of Chemokine and Immune Checkpoint Traps To Treat Pancreatic Cancer.ACS nano · 2017Article
- Molecular therapeutics in pancreas cancer.World journal of gastrointestinal oncology · 2016Review
- Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity.Molecular oncology · 2015Review
- Pathological and molecular evaluation of pancreatic neoplasms.Seminars in oncology · 2015Review
- Specificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancer.Seminars in oncology · 2014Review
Corrections and comments
- Comment on
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
An agonist CD40 monoclonal antibody (CP-870,893), in combination with gemcitabine, is well tolerated in patients with advanced pancreatic adenocarcinoma. The combination results in induction of cytokines, B cell activation, and clinical responses. These findings support testing of immunotherapies in combination with other established and targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.